Chronic opioid therapy urine drug testing in primary care: prevalence and predictors of aberrant results
- PMID: 25217208
- PMCID: PMC4242878
- DOI: 10.1007/s11606-014-3010-y
Chronic opioid therapy urine drug testing in primary care: prevalence and predictors of aberrant results
Abstract
Background: Urine drug tests (UDTs) are recommended for patients on chronic opioid therapy (COT). Knowledge of the risk factors for aberrant UDT results could help optimize their use.
Objective: To identify primary care COT patient and opioid regimen characteristics associated with aberrant UDT results.
Design: Population-based observational.
Sample: 5,420 UDTs for Group Health integrated group practice COT patients.
Measures: Group Health database measures of patient demographics, medical history, COT characteristics, and UDT results.
Results: Thirty percent of UDTs had aberrant results, including prescribed opioid non-detection (12.3%), tetrahydrocannabinol (THC; 11.2%), non-prescribed opioid (5.3%), illicit drug (excluding THC; 0.6%), non-prescribed benzodiazepine (1.7%), and dilute (4.8%). Adjusted odds ratios (95% CI) of any aberrant result were higher for males than females (1.24 [1.07, 1.43]), patients with versus without prior substance use disorder diagnoses (1.42 [1.17, 1.72]), and current smokers versus non-smokers (1.50 [1.30, 1.73]). Odds ratios were lower for patients aged 45-64 (0.77 [0.65, 0.92]) and 65+ (0.40 [0.32, 0.50]) versus patients aged 20-44 and for patients on long-acting opioids only (0.72 [0.55, 0.95]) or long-acting plus short-acting (0.67 [0.54, 0.83]) versus short-acting only. Adjusted odds of prescribed opioid non-detection were lower for patients aged 45-64 (0.79 [0.63, 0.998]) and 65+ (0.44 [0.32, 0.59]) versus patients aged 20-44, for those on 40-<120 mg daily morphine-equivalent dose (0.52 [0.39, 0.70]) or 120+ mg (0.22 [0.11, 0.43]) versus <40 mg, and for patients on long-acting (0.35 [0.21, 0.57]) or long-acting plus short-acting (0.35 [0.24, 0.50]) opioids (versus short-acting only); and odds ratios were higher for patients with versus without prior diagnoses of substance use disorder (1.70 [1.31, 2.20]).
Conclusions: In this primary care setting, results were aberrant for 30% of UDTs of COT patients, largely because of prescribed opioid non-detection and THC. Aberrant results of almost all types were more likely among patients under the age of 45. Other risk factors varied across aberrancies, but commonly included current smoking and prior substance use disorder diagnosis.
Comment in
-
Capsule commentary on Turner et al., chronic opioid therapy urine drug testing in primary care: prevalence and predictors of aberrant results.J Gen Intern Med. 2015 Feb;30(2):241. doi: 10.1007/s11606-014-3091-7. J Gen Intern Med. 2015. PMID: 25387440 Free PMC article. No abstract available.
Similar articles
-
Do Urine Drug Tests Reveal Substance Misuse Among Patients Prescribed Opioids for Chronic Pain?J Gen Intern Med. 2022 Aug;37(10):2365-2372. doi: 10.1007/s11606-021-07095-8. Epub 2021 Aug 17. J Gen Intern Med. 2022. PMID: 34405344 Free PMC article.
-
Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results.J Gen Intern Med. 2014 Feb;29(2):305-11. doi: 10.1007/s11606-013-2651-6. Epub 2013 Oct 19. J Gen Intern Med. 2014. PMID: 24142119 Free PMC article.
-
Treatment changes following aberrant urine drug test results for patients prescribed chronic opioid therapy.J Opioid Manag. 2015 Jan-Feb;11(1):45-51. doi: 10.5055/jom.2015.0251. J Opioid Manag. 2015. PMID: 25750164
-
A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management.Postgrad Med. 2011 Nov;123(6):124-31. doi: 10.3810/pgm.2011.11.2502. Postgrad Med. 2011. PMID: 22104461 Review.
-
Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.Postgrad Med. 2011 Nov;123(6):132-9. doi: 10.3810/pgm.2011.11.2503. Postgrad Med. 2011. PMID: 22104462 Review.
Cited by
-
Disagreement and Uncertainty Among Experts About how to Respond to Marijuana Use in Patients on Long-term Opioids for Chronic Pain: Results of a Delphi Study.Pain Med. 2020 Feb 1;21(2):247-254. doi: 10.1093/pm/pnz153. Pain Med. 2020. PMID: 31393585 Free PMC article.
-
Identifying and assessing the risk of opioid abuse in patients with cancer: an integrative review.Subst Abuse Rehabil. 2016 Jun 2;7:71-9. doi: 10.2147/SAR.S85409. eCollection 2016. Subst Abuse Rehabil. 2016. PMID: 27330340 Free PMC article. Review.
-
Provider Misinterpretation, Documentation, and Follow-Up of Definitive Urine Drug Testing Results.J Gen Intern Med. 2020 Jan;35(1):283-290. doi: 10.1007/s11606-019-05514-5. Epub 2019 Nov 11. J Gen Intern Med. 2020. PMID: 31713040 Free PMC article.
-
Development and Performance of a Web-Based Tool to Adjust Urine Toxicology Testing Frequency: Retrospective Study.JMIR Med Inform. 2020 Apr 22;8(4):e16069. doi: 10.2196/16069. JMIR Med Inform. 2020. PMID: 32319958 Free PMC article.
-
Do Urine Drug Tests Reveal Substance Misuse Among Patients Prescribed Opioids for Chronic Pain?J Gen Intern Med. 2022 Aug;37(10):2365-2372. doi: 10.1007/s11606-021-07095-8. Epub 2021 Aug 17. J Gen Intern Med. 2022. PMID: 34405344 Free PMC article.
References
-
- Warner M, Chen LH, Makuc DM, Anderson RN, Minino AM. Drug poisoning deaths in the United States, 1980–2008. NCHS data brief, no. 81. National Center for Health Statistics. 2011 [Accessed August 13, 2014]. Available at: http://www.cdc.gov/nchs/data/databriefs/db81.htm. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous